Spyre Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SYRE Nasdaq 2836 www.spyre.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Spyre Therapeutics, Inc.

Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - Jun 15th, 2026 6:00 am
Spyre Therapeutics Announces Grants of Inducement Awards - Jun 5th, 2026 2:01 pm
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up - Jun 4th, 2026 8:56 am
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential - Jun 4th, 2026 3:07 am
Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA - Jun 3rd, 2026 6:00 am
Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License Terms - Jun 2nd, 2026 4:07 pm
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares - May 17th, 2026 1:13 pm
Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares - May 17th, 2026 1:01 pm
This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million - May 17th, 2026 12:52 pm
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million - May 17th, 2026 12:42 pm
Damora Therapeutics (DMRA) Appoints Jennifer Jarrett as President, Chief Executive Officer - May 5th, 2026 11:05 am
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 5th, 2026 6:00 am
Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise - May 1st, 2026 1:09 pm
Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now? - Apr 30th, 2026 7:57 am
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers - Apr 27th, 2026 3:15 pm
Here’s What Raymond James Says About Spyre Therapeutics Inc (SYRE) - Apr 23rd, 2026 3:47 am
Spyre (SYRE) Climbs 42% as Treatment Candidate Poses ‘Best-in-Class’ Potential - Apr 19th, 2026 6:50 pm
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million - Apr 16th, 2026 2:15 pm
Spyre Therapeutics (SYRE) Is Up 32.7% After $403 Million Equity Raise On Positive Phase 2 Data - Apr 16th, 2026 2:06 am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Investors Turn to Corporate Earnings - Apr 15th, 2026 7:19 am